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LETTER TO THE EDITOR
Rupture of a Cerebral
Arteriovenous
Malformation in a
Patient Treated with
Bevacizumab
To the Editor:
A previously healthy 52-year-old
man presented with recurrent pneumonia.
A computerized tomography scan demon-
strated a right upper lobe mass, multiple
mediastinal adenopathy, and pleural effu-
sion. Biopsy revealed poorly differenti-
ated non-small cell carcinoma. Magnetic
resonance imaging of the brain showed no
evidence of metastasis; however, a 2.5-cm
arteriovenous malformation (AVM) near
the Sylvian fissure was identified. A recon-
structed maximum-intensity-projection im-
age demonstrated a tangle of vessels on the
left, with large vein draining to the superior
sagittal sinus (Figure 1). Paclitaxel (200 mg/
m2), carboplatin (AUC 6), and bevacizumab
(15mg/kg)was administered. The first cycle
of treatment was well tolerated; however, 4
days after the second cycle, the patient be-
came obtunded and developed respiratory
failure. Computed tomography scan of the
brain revealed massive intracerebral hemor-
rhagewith transfalcine herniation (Figure 2).
Platelet count and coagulation parameters
were within the normal ranges. Despite vig-
orous supportive measures, the patient died
shortly thereafter.
AVMs of the brain are focal abnor-
mal conglomerations of dilated arteries
and veins within brain parenchyma.1
These vessels connect directly without a
capillary bed, resulting in a high pressure
being imposed upon the venous portion
(which frequently harbors an incompetent
elastic lamina) and a tendency to rupture.
Rupture of AVM is associated with 5 to
10% mortality and 30 to 50% permanent
neurologic deficit rates. The prevalence of
AVMs is approximately 0.01% of the gen-
eral population. The risk of hemorrhage is
estimated at 2 to 4% per year; however,
higher risks were observed among AVMs
with associated aneurysm, drainage to
deep venous sinus, single draining vein, or
history of previous rupture.
To our knowledge, rupture of
AVMs of the brain has never been linked
to bevacizumab, although a bleeding ten-
dency at the tumor site and in the gastro-
intestinal tract has been associated with
bevacizumab treatment. Bevacizumab, a
monoclonal antibody against vascular en-
dothelial growth factor, is approved by the
Food and Drug Administration for treat-
ment of advanced non-small cell lung,
breast, and colon cancer.2 Phase II study
of bevacizumab in non-small cell lung
cancer reported a severe or fatal hemop-
tysis in 31% of patients with squamous
carcinomas and 2.3% of patients with
nonsquamous histology.3 In a phase III
study, excluding patients with brain
metastasis, squamous histology or an-
ticoagulation, the incidence of serious
bleeding events was still significantly
higher among patients receiving car-
boplatin/paclitaxel plus bevacizumab
than those receiving carboplatin/pacli-
taxel alone.4 After marketing of the
drug, cases of intracerebral hemor-
rhage associated with concurrent bev-
acizumab and anticoagulation therapy
have also been reported.
Bleeding tendency associated
with bevacizumab is believed to result
from an endothelial dysfunction and
weakened supporting layers of blood
vessels. Most bleeding complications
are minor, including mucocutaneous
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FIGURE 1. Maximum intensity projection reconstruction of the source data.
Craniocaudal view demonstrates a tangle of vessels on the left with large vein
draining to the superior sagittal sinus.
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bleeding and epistaxis. Interestingly,
bevacizumab has been associated with
a regression of hepatic AVMs in one
patient with hereditary hemorrhagic
telangiectasia.5 Although it is possible
that bleeding of AVM in our patient
occurred by chance, we believe that
for patients with advanced cancer and
AVMs of brain, treatment regimens
that include bevacizumab should be
used only after careful consideration,
as treatment-related risks may out-
weigh benefits.
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FIGURE 2. Noncontrast computed tomography of the brain demonstrates a large left
intraparenchymal hematoma with mass effect and transfalcine herniation of the brain.
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